<DOC>
	<DOCNO>NCT00087074</DOCNO>
	<brief_summary>This phase II trial study well CCI-779 work treat patient soft tissue sarcoma gastrointestinal stromal tumor . Drugs use chemotherapy , CCI-779 , work different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>CCI-779 Treating Patients With Soft Tissue Sarcoma Gastrointestinal Stromal Tumor</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess antitumor activity CCI-779 patient population . SECONDARY OBJECTIVES : I . To assess follow patient soft tissue sarcoma follow treatment CCI-779 : duration response , time progression , survival . TERTIARY OBJECTIVES : I . To describe correlate follow patient characteristic outcome patient population follow treatment CCI-779 : relative level 4EBP1 eIF4E , phospho 4EBP1 , total phospho ribosomal S6 pretreatment tumor tissue , expression level EGFR , activate EGFR , Her2 , c-Myc , phospho Akt , total Akt , phospho-mTOR total mTOR pretreatment tumor tissue , drug induce inhibition p70S6 kinase activity , phosphorylation S6 PBMC , relative level serum sirolimus post-treatment sample . OUTLINE : Patients receive CCI-779 IV 30 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course beyond CR . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically cytologic confirm soft tissue sarcoma Measurable disease ; patient lesion measure least 1 cm less 2 cm , must use spiral CT image pre posttreatment tumor assessment Absolute neutrophil count ( ANC ) &gt; = 1,500/μL Platelets ( PLTS ) &gt; = 100,000/μL Hgb &gt; = 10.0 g/dL Direct bilirubin = &lt; 1.5 x ULN ( upper limit normal ) AST ( SGOT ) = &lt; 2.5 x ULN = &lt; 5 x ULN* liver metastases present ALT ( SGPT ) = &lt; 2.5 x ULN = &lt; 5 x ULN* liver metastases present Creatinine = &lt; 1.5 x ULN , great , creatinine clearance &gt; = 50 mL/min/1.73 m^2 Baseline glucose level Fasting serum cholesterol = &lt; 350 mg/dL ( 9.0 mmol/L ) Fasting triglyceride = &lt; 400 mg/dL ( 4.56 mmol/L ) ECOG Performance Status ( PS ) 0 , 1 2 Life expectancy &gt; = 12 week Capable understanding investigational nature , potential risk benefit study , able provide valid informed consent Any follow regimen may harmful develop fetus nursing child : Pregnant woman Breastfeeding woman Men woman childbearing potential sexual partner unwilling employ adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) Any follow : Nitrosoureas mitomycin = &lt; 6 week prior study entry Other chemotherapy = &lt; 4 week prior study entry Radiotherapy = &lt; 4 week prior study entry Concurrent use investigation agent Adverse event due agent administer = &lt; 4 week prior study entry History allergic reaction attribute compound similar chemical biologic composition CCI779 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , diabetes , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Known HIVpositive patient receive combination antiretroviral therapy Prior chemotherapy metastatic disease Exceptions : Patients GIST fail Gleevec eligible Patients adjuvant/neoadjuvant chemotherapy also eligible Known brain metastasis Exception : Patients treat brain metastatic disease stable symptom treatment &gt; = 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>